Get the Stockscreener App
2.84
0.35%
-0.01
After Hours:
2.84
Savara Inc stock is traded at $2.84, with a volume of 389.91K.
It is down -0.35% in the last 24 hours and down -6.89% over the past month.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
See More
Previous Close:
$2.85
Open:
$2.84
24h Volume:
389.91K
Relative Volume:
0.29
Market Cap:
$487.40M
Revenue:
-
Net Income/Loss:
$-54.70M
P/E Ratio:
-8.6061
EPS:
-0.33
Net Cash Flow:
$-51.36M
1W Performance:
+1.43%
1M Performance:
-6.89%
6M Performance:
-32.06%
1Y Performance:
-40.83%
1-Day Range:
$2.80
$2.88
1-Week Range:
$2.624
$2.91
52-Week Range:
$2.59
$5.70
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
2.84 | 487.40M | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Investing in Savara Inc (SVRA) Is Getting More Attractive - Knox Daily
Savara Inc. to Present at Upcoming Healthcare Investor Conferences - MSN
Savara Inc. Publishes Promising Long-Term Outcomes for aPAP Treatment - MSN
Analysts Predict How High Savara Inc (SVRA) Will Go. - Stocks Register
JPMorgan Chase & Co. Purchases 13,420 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Molgramostim shows promise in rare lung disease treatment - MSN
SVRA stock touches 52-week low at $2.6 amid market challenges - MSN
Savara Inc. Announces Manuscript on Long-Term Outcomes with Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis Published in ERJ Open Research - Marketscreener.com
Savara Announces Participation in Upcoming Healthcare Investor Conferences - The Bakersfield Californian
Rare Disease Pioneer Savara Takes Center Stage at Major Healthcare Investment Forums - StockTitan
Savara Inc (NASDAQ:SVRA) Receives $9.86 Average PT from Brokerages - Defense World
Savara Inc (NASDAQ:SVRA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Title: Savara Inc. Approves 2025 Executive Officers’ Target Bonus Amounts - Defense World
Savara sets executive bonus targets for 2025 - MSN
Savara sets executive bonus targets for 2025 By Investing.com - Investing.com Australia
Savara Sets 2025 Executive Bonus Targets - TipRanks
Savara Inc Updates Corporate Presentation in Latest SEC Filing - Defense World
Savara (NASDAQ:SVRA) Stock Price Down 5.3%Here's What Happened - MarketBeat
Savara Inc. Launches Early Access Program for Rare Lung Disease Treatment - MSN
Savara Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference - MSN
Savara (NASDAQ:SVRA) Shares Up 8.1%Should You Buy? - MarketBeat
Barclays PLC Buys 158,244 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara Highlights MOLBREEVI’s Potential in Rare Disease Market - TipRanks
Institutional investors may adopt severe steps after Savara Inc.'s (NASDAQ:SVRA) latest 11% drop adds to a year losses - Simply Wall St
Savara Inc (NASDAQ:SVRA) Shares Sold by Jane Street Group LLC - Defense World
SVRA Stock Touches 52-Week Low at $2.81 Amid Market Challenges By Investing.com - Investing.com South Africa
SVRA Stock Touches 52-Week Low at $2.81 Amid Market Challenges - Investing.com Australia
Savara Inc. Grants Inducement Awards to New Employees - MSN
Principal Financial Group Inc. Sells 7,607 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ:SVRA) Receives $9.86 Average Price Target from Brokerages - Defense World
Savara Inc (NASDAQ:SVRA) Receives $9.86 Consensus Target Price from Analysts - MarketBeat
Geode Capital Management LLC Raises Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
Geode Capital Management LLC Buys 264,825 Shares of Savara Inc (NASDAQ:SVRA) - MarketBeat
Barclays PLC Increases Stock Position in Savara Inc (NASDAQ:SVRA) - Defense World
Who Really Pulls the Strings at Savara? Discover the Power Players! - Jomfruland.net
Savara Inc. (NASDAQ:SVRA) is largely controlled by institutional shareholders who own 53% of the company - Yahoo Finance
Savara Begins FDA Submission for Rare Lung Disease Treatment - MSN
State Street Corp Acquires 560,242 Shares of Savara Inc (NASDAQ:SVRA) - MarketBeat
State Street Corp Purchases 560,242 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):